Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

被引:4
作者
Ghobadian, Ala [1 ]
Mokhtari, Saba [2 ]
Shariati, Behnam [1 ]
Kamalzadeh, Leila [1 ]
Shati, Mohsen [3 ,4 ]
Ardebili, Mehrdad Eftekhar [1 ]
Yarahmadi, Masoomeh [1 ]
Shalbafan, Mohammadreza [1 ,5 ]
机构
[1] Iran Univ Med Sci, Mental Hlth Res Ctr, Sch Med, Psychosocial Hlth Res Inst PHRI,Dept Psychiat, Tehran, Iran
[2] Univ Social Welf & Rehabil Sci, Dept Psychiat, Tehran, Iran
[3] Iran Univ Med Sci, Mental Hlth Res Ctr MHRC, Sch Behav Sci & Mental Hlth, Tehran Inst Psychiat, Tehran, Iran
[4] Iran Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Tehran, Iran
[5] Inst Cognit Sci Studies, Brain & Cognit Clin, Tehran, Iran
关键词
Serotonin; 5-HT3; receptor; Obsessive-compulsive disorder; Randomized controlled trial; Selective serotonin reuptake inhibitors; Granisetron; SEROTONIN REUPTAKE INHIBITORS; MAJOR DEPRESSIVE DISORDER; ANTIPSYCHOTIC AUGMENTATION; COMBINATION THERAPY; L-CARNOSINE; FLUVOXAMINE; MODERATE; EPIDEMIOLOGY; ONDANSETRON; RECEPTOR;
D O I
10.1186/s40360-022-00610-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20-30%, and satisfactory treatment is obtained in 40-60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the patients' function. Therefore, it is necessary to investigate possible strategies to improve the mitigation of symptoms. In this study, the main objective was to examine and investigate the effectiveness of granisetron, which is a serotonin 5-hydroxytryptamine receptor type 3 (5-HT3) antagonist, as an adjunct therapy to selective serotonin reuptake inhibitors, for the purpose of ameliorating OCD symptoms. Methods fifty-eight patients diagnosed with OCD, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, who had a Yale-Brown obsessive-compulsive scale (Y-BOCS) score of more than 21 were recruited in a double-blinded, parallel-group, placebo-controlled, clinical trial of 10 weeks to receive either granisetron (1 mg twice daily) and sertraline (100 mg daily initially followed by 200 mg daily after week 4) or placebo and sertraline. The primary outcome was OCD symptoms measured by the Y-BOCS. Results Y-BOCS total score significantly dropped in both groups (28.9 to 17.7 for granisetron plus sertraline and 27.5 to 19.3 for placebo plus sertraline group with a slightly greater drop for granisetron plus sertraline group), while the granisetron plus sertraline group experienced a significantly greater reduction in obsession scores (Greenhouse-Geisser F(2.32,97.57) = 4.52,p-value = 0.01). Moreover, in comparison with the placebo plus sertraline group, the proportion of the patients showing complete response was considerably higher among the granisetron plus sertraline group (P-value < 0.01). No major adverse effects were observed in any of the groups. Conclusion The results suggest that granisetron augmentation of sertraline may increase the rate of response in patients with moderate to severe non-refractory OCD. Further studies are suggested in this regard.
引用
收藏
页数:10
相关论文
共 41 条
[1]   Granisetron: An update on its clinical use in the management of nausea and vomiting [J].
Aapro, M .
ONCOLOGIST, 2004, 9 (06) :673-686
[2]   Clinical predictors of health-related quality of life in obsessive-compulsive disorder [J].
Albert, Umberto ;
Maina, Giuseppe ;
Bogetto, Filippo ;
Chiarle, Alice ;
Mataix-Cols, David .
COMPREHENSIVE PSYCHIATRY, 2010, 51 (02) :193-200
[3]   Nausea and the quest for the perfect anti-emetic [J].
Andrews, Paul L. R. ;
Sanger, Gareth J. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 722 :108-121
[4]  
[Anonymous], 2014, F1000PRIME REPORTS
[5]  
APA, 1980, Diagnostic and statistical manual of mental disorders
[6]   L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study [J].
Arabzadeh, Somaye ;
Shahhossenie, Maryam ;
Mesgarpour, Bita ;
Rezaei, Farzin ;
Shalbafan, Mohammad Reza ;
Ghiasi, Zahra ;
Akhondzadeh, Shahin .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2017, 32 (04)
[7]   L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial [J].
Araminia, Behin ;
Shalbafan, Mohammadreza ;
Mortezaei, Amirhosein ;
Shirazi, Elham ;
Ghaffari, Salomeh ;
Sahebolzamani, Erfan ;
Mortazavi, Seyyed Hosein ;
Shariati, Behnam ;
Ardebili, Mehrdad Eftekhar ;
Aqamolaei, Ali ;
Naderi, Sina ;
Akhondzadeh, Shahin .
JOURNAL OF AFFECTIVE DISORDERS, 2020, 267 :131-136
[8]   Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Askari, Neda ;
Moin, Mandieh ;
Sanati, Mohammad ;
Tajdini, Masih ;
Hosseini, Seyed-Mohammad-Reza ;
Modabbernia, Amirhossein ;
Najand, Babak ;
Salimi, Samrand ;
Tabrizi, Mina ;
Ashrafi, Mandana ;
Hajiaghaee, Reza ;
Akhondzadehl, Shahin .
CNS DRUGS, 2012, 26 (10) :883-892
[9]   OCD: obsessive-compulsive ... disgust? The role of disgust in obsessive-compulsive disorder [J].
Bhikram, Tracy ;
Abi-Jaoude, Elia ;
Sandor, Paul .
JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2017, 42 (05) :300-306
[10]   A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder [J].
Bloch, M. H. ;
Landeros-Weisenberger, A. ;
Kelmendi, B. ;
Coric, V. ;
Bracken, M. B. ;
Leckman, J. F. .
MOLECULAR PSYCHIATRY, 2006, 11 (07) :622-632